Patents Examined by D Margaret M Seaman
  • Patent number: 10292395
    Abstract: In crop production in the fields of agriculture, horticulture and the like, the damage caused by insect pests etc. is still immense, and insect pests resistant to existing insecticides have emerged. Under such circumstances, the development of novel agricultural and horticultural insecticides is desired. The present invention provides an agricultural and horticultural insecticide comprising, as an active ingredient, a 3H-pyrrolopyridine compound represented by the general formula (1): (wherein A1, A2, and A3 each represent a nitrogen atom or a CH group, R1 represents an ethyl group, R2 and R4 each represent a hydrogen atom, R3 and R7 each represent a haloalkyl group, R5 and R6 each represent a fluorine atom, and m represents 0 or 2), an N-oxide thereof or a salt thereof; and a method for using the agricultural and horticultural insecticide.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 21, 2019
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Ikki Yonemura, Yusuke Sano, Akiyuki Suwa, Shunpei Fujie
  • Patent number: 10286082
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: May 14, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein
  • Patent number: 10286083
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: May 14, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein
  • Patent number: 10273213
    Abstract: The present invention provides methods of preparing Praziquantel, in particular (R)-Praziquantel and analogues thereof in a stereoselective manner. One method involves asymmetric hydrogenation of the following intermediate compound and subsequent cyclization.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 30, 2019
    Assignee: Merck Patent GmbH
    Inventors: Luc Eberhardt, Andreas Waechtler, David Maillard, Stefan Lehmann
  • Patent number: 10273221
    Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: April 30, 2019
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Farhan Bou Hamdan, Laura Quaranta, Stephan Trah, Matthias Weiss
  • Patent number: 10266512
    Abstract: Processes for preparing heteroatom containing cyclic dimers that result in increased production efficiency and reduced waste production.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 23, 2019
    Assignee: Novus International, Inc.
    Inventors: Xiaojun Wang, Mark A. Hochwalt, Graciela B. Arhancet
  • Patent number: 10266495
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R8 are described herein.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 23, 2019
    Assignee: FORMA TM2, INC.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Patent number: 10259790
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 16, 2019
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Patent number: 10259791
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: April 16, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Patent number: 10253015
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 9, 2019
    Assignee: FORMA TM2, INC.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Patent number: 10246457
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 2, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Michael D. Altman, Brian M. Andresen, Jian Liu, Joseph Kozlowski, Sobhana Babu Boga, Younong Yu, Rajan Anand, Jiaqiang Cai, Dahai Wang, Shilan Liu
  • Patent number: 10246437
    Abstract: The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The novel crystalline forms of Neratinib maleate in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • Patent number: 10227300
    Abstract: An N-substituted triacetonediamine compound is prepared by reacting 4-amino-2,2,6,6-tetramethylpiperidine or a derivative thereof with a carbonyl compound in a reductive amination, wherein reductive conditions are established by conducting the reaction in the presence of hydrogen and in the presence of a supported catalyst, wherein the supported catalyst includes at least one metal M, wherein the metal M is selected from the group consisting of V, Cr, Mo, Mn, Ni, Pd, Pt, Fe, Ru, Os, Co, Rh, Ir, and Cu.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 12, 2019
    Assignee: Evonik Degussa GmbH
    Inventors: Benjamin Willy, Jochen Niemeyer, Guenter Kreilkamp, Beatrix Vom Bruch, Manfred Neumann, Michael Keup
  • Patent number: 10227355
    Abstract: The patent discloses novel quinoline derivatives of formula (I), (Formula should be inserted here) and process for preparing the same. The compounds of formula (I) can be further used for the synthesis of Inhibitors like Kinase Tyrosine Inhibitors.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 12, 2019
    Assignee: Council of Scientific and Industrial Research
    Inventors: Ekambaram Balaraman, Siba Prasad Midya, Garima Jaiswal
  • Patent number: 10227353
    Abstract: Methods that may be used for the manufacture of a class of chemical compounds known as morphinans, including neopine, are provided. Compositions useful for the synthesis of morphinans, including neopine, are also provided.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 12, 2019
    Assignee: Epimeron Inc.
    Inventor: Peter James Facchini
  • Patent number: 10227302
    Abstract: What is described is a compound wherein R1 and R2 are the same or different, each a linear or branched alkyl consisting of 1 to 20 carbons, or a linear or branched alkenyl or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a bond, a linear alkylene of 1-18 carbons, or a linear alkenylene consisting of 2 to 18 carbons; L3 is a bond or a linear or branched alkylene consisting of 1 to 6 carbons; L4 is a bond or a methylene; X is S or O, R3 is a linear or branched alkylene consisting of 1 to 6 carbons, and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: March 12, 2019
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, Steven P. Tanis
  • Patent number: 10220030
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 5, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam Kenneth Charnley, Pamela A. Haile, Robert W. Marquis, Jr., John F. Mehlmann, Joseph J. Romano, Robert R. Singhaus, Jr., Gren Z. Wang
  • Patent number: 10220105
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification of 18F-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: March 5, 2019
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Duncan George Wynn, Steven Michael Fairway, Matthias Eberhard Glaser, Ian Newington, Gareth Edwin Smith, Imtiaz Ahmed Khan, Julian Grigg
  • Patent number: 10221140
    Abstract: The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 5, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ravi K. Amaravadi, Jeffrey Winkler
  • Patent number: 10214548
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: February 26, 2019
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, Eric Easom, Yvonne Freund, Jacob J. Plattner, Jessica Sligar, Daitao Chen, Jennifer Freeman, Joe Perales